MARKET

TTNP

TTNP

Titan Pharmaceut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4999
+0.0098
+2.00%
Opening 09:33 05/18 EDT
OPEN
0.5199
PREV CLOSE
0.4901
HIGH
0.5199
LOW
0.4999
VOLUME
6.52K
TURNOVER
1.60K
52 WEEK HIGH
3.100
52 WEEK LOW
0.4805
MARKET CAP
6.02M
P/E (TTM)
-0.5521
1D
5D
1M
3M
1Y
5Y
Activist Investing Announces 5.6% Ownership Interest In Titan Pharmaceuticals
ctivist Investing LLC (together with its affiliates, "Activist Investing" or "we"), today filed a Schedule 13D announcing its acquisition of approximately 5.6% of the common stock
Benzinga · 04/25 17:31
Activist Investing Announces 5.6% Ownership Interest in Titan Pharmaceuticals, Inc.
NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Activist Investing LLC (together with its affiliates, “Activist Investing” or “we”), today filed a Schedule 13D announcing its acquisition of approximately 5.6% of the common stock outstanding of Titan Pharmaceu...
GlobeNewswire · 04/25 17:29
Activist Investing Acquires Minority Stake in Titan Pharmaceuticals
MT Newswires · 04/25 14:24
Titan Pharmaceuticals Expects to Raise $5.5 Million from Direct Offering, Private Placement Priced At-The-Market
MT Newswires · 02/03 03:38
Titan Pharmaceuticals Raises $5.5M Via Equity
Titan Pharmaceuticals Inc (NASDAQ: TTNP) has announced a private placement of 3.37 million shares and 1.29 million pre-funded warrants.
Benzinga · 02/02 17:27
Titan Pharmaceuticals to raise $5.5M in stock and pre-funded warrant offering
Titan Pharmaceuticals (NASDAQ:TTNP) trades 3.9% lower premarket after it entered into a securities purchase agreement with a single institutional investor to purchase 3.37M shares in a registered direct offering priced at-the-market. In a
Seekingalpha · 02/02 14:08
BRIEF-Titan Pharmaceuticals Announces Pricing Of $5.5 Mln Registered Direct And Pipe Offering Priced At-The-Market
reuters.com · 02/02 13:54
Titan Pharmaceuticals Prices $5.5M Registered Direct And PIPE Offering Priced At-The-Market; Combined Offering Price Of Each Share Or Pre-Funded Warrant $1.18
SOUTH SAN FRANCISCO, Calif., Feb. 2, 2022 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today announced that it has entered into a securities purchase
Benzinga · 02/02 13:46
More
No Data
Learn about the latest financial forecast of TTNP. Analyze the recent business situations of Titan Pharmaceut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average TTNP stock price target is 7.00 with a high estimate of 7.00 and a low estimate of 7.00.
High7.00
Average7.00
Low7.00
Current 0.5180
EPS
Actual
Estimate
-1.06-0.80-0.53-0.27
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 40
Institutional Holdings: 496.76K
% Owned: 4.13%
Shares Outstanding: 12.04M
TypeInstitutionsShares
Increased
3
36.29K
New
8
91.01K
Decreased
5
95.10K
Sold Out
7
27
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.06%
Pharmaceuticals & Medical Research
+1.51%
Key Executives
Chairman/Executive Director
Marc Rubin
President/Chief Operating Officer/Director
Katherine DeVarney
Independent Director
Joseph Akers
Independent Director
M. David MacFarlane
Independent Director
James McNab
Independent Director
Scott Smith
No Data
No Data
About TTNP
Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. It operates in one business segment, which provides the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. Its product Probuphine implant is based on ProNeura technology, which is used for the maintenance treatment of opioid use disorder in clinically stable patients. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, namely Kappa Opioid Agonist Peptide Program and Nalmefene Development Program. Its kappa opioid agonist peptide (TP-2021) uses ProNeura technology to provide a non-addictive treatment for certain types of pain.

Webull offers kinds of Titan Pharmaceuticals, Inc. stock information, including NASDAQ:TTNP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TTNP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TTNP stock methods without spending real money on the virtual paper trading platform.